GNMSF (Genmab AS) Other Financing: $-269 Mil (TTM As of Mar. 2026)


GNMSF Genmab AS GNMSF
93 GF Score
Price $275.00
GF Value $337.53
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Other Financing?

Genmab AS GNMSF 93 Other Financing is $-269 Mil as of Mar. 2026. GuruFocus rates GNMSF with a GF Score™ of 93/100 and a GF Value™ of $337.53 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Genmab AS's Other Financing for the three months ended in Mar. 2026 was $-12 Mil.

Genmab AS's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-269 Mil.

Genmab AS Other Financing Historical Data

* Premium members only.

The historical data trend for Genmab AS's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Other Financing Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.94 27.64 6.00 3.00 -268.00

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.00 4.00 8.00 -269.00 -12.00
GNMSF
93GF Score
Genmab AS GNMSF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-269 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-269 Mil mean?
Genmab AS (GNMSF) has a Other Financing of $-269 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Genmab AS and its competitors.
Is Genmab AS's Other Financing too high?
Genmab AS's current Other Financing is $-269 Mil. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Other Financing compare to VRTX and REGN?
Genmab AS's Other Financing of $-269 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Genmab AS and its competitors. Genmab AS's current Other Financing is $-269 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $337.53, compared to a current price of $275.00 — trading 18.5% below its estimated fair value. The current Other Financing is $-269 Mil. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Other Financing is $-269 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $275.00 is trading 18.5% below its estimated GF Value™ of $337.53. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • Other Financing: $-269 Mil
  • GF Value™: $337.53 vs. price of $275.00 (18.5% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for GNMSF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$275.00
Price
$337.53
GF Value